pLenti-EmGFP-LATS2/1 KD Citations (4)

Originally described in: Screening with a novel cell-based assay for TAZ activators identifies a compound that enhances myogenesis in C2C12 cells and facilitates muscle repair in the muscle injury model.
Yang Z, Nakagawa K, Sarkar A, Maruyama J, Iwasa H, Bao Y, Ishigami-Yuasa M, Ito S, Kagechika H, Hata S, Nishina H, Abe S, Kitagawa M, Hata Y Mol Cell Biol. 2014 Feb 18. PubMed Journal

---

Articles Citing pLenti-EmGFP-LATS2/1 KD

Articles
The Hippo pathway regulates human megakaryocytic differentiation. Lorthongpanich C, Jiamvoraphong N, Supraditaporn K, Klaihmon P, U-Pratya Y, Issaragrisil S. Thromb Haemost. 2017 Jan 5;117(1):116-126. doi: 10.1160/TH16-07-0564. Epub 2016 Oct 27. PubMed
WIP Drives Tumor Progression through YAP/TAZ-Dependent Autonomous Cell Growth. Gargini R, Escoll M, Garcia E, Garcia-Escudero R, Wandosell F, Anton IM. Cell Rep. 2016 Nov 15;17(8):1962-1977. doi: 10.1016/j.celrep.2016.10.064. PubMed
p190A RhoGAP induces CDH1 expression and cooperates with E-cadherin to activate LATS kinases and suppress tumor cell growth. Ouyang H, Luong P, Frodin M, Hansen SH. Oncogene. 2020 Aug;39(33):5570-5587. doi: 10.1038/s41388-020-1385-2. Epub 2020 Jul 8. PubMed
Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib. Klaihmon P, Lorthongpanich C, Kheolamai P, Saisaard W, Issaragrisil S. Sci Rep. 2024 Feb 18;14(1):3993. doi: 10.1038/s41598-024-54728-z. PubMed

If you have published an article using this material, please email us at to have your article added to this page.